Morgan Stanley Xtl Biopharmaceuticals LTD Call Options Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding XTLB
# of Institutions
6Shares Held
453KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$361,9760.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$361,9760.13% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il15.4KShares$28,0910.0% of portfolio
-
Rhumbline Advisers Boston, MA6.52KShares$11,8640.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $9.92M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...